Due to the reactive medical approach applied to disease management, stroke has reached an epidemic scale worldwide. In 2019, the global stroke prevalence was 101.5 million people, wherefrom 77.2 million (about 76%) suffered from ischemic stroke; 20.7 and 8.4 million suffered from intracerebral and subarachnoid haemorrhage, respectively. Globally in the year 2019 - 3.3, 2.9 and 0.4 million individuals died of ischemic stroke, intracerebral and subarachnoid haemorrhage, respectively. During the last three decades, the absolute number of cases increased substantially. The current prevalence of stroke is 110 million patients worldwide with more than 60% below the age of 70 years. Prognoses by the World Stroke Organisation are pessimistic: globally, it is predicted that 1 in 4 adults over the age of 25 will suffer stroke in their lifetime. Although age is the best known contributing factor, over 16% of all strokes occur in teenagers and young adults aged 15-49 years and the incidence trend in this population is increasing. The corresponding socio-economic burden of stroke, which is the leading cause of disability, is enormous. Global costs of stroke are estimated at 721 billion US dollars, which is 0.66% of the global GDP. Clinically manifested strokes are only the "tip of the iceberg": it is estimated that the total number of stroke patients is about 14 times greater than the currently applied reactive medical approach is capable to identify and manage. Specifically, lacunar stroke (LS), which is characteristic for silent brain infarction, represents up to 30% of all ischemic strokes. Silent LS, which is diagnosed mainly by routine health check-up and autopsy in individuals without stroke history, has a reported prevalence of silent brain infarction up to 55% in the investigated populations. To this end, silent brain infarction is an independent predictor of ischemic stroke. Further, small vessel disease and silent lacunar brain infarction are considered strong contributors to cognitive impairments, dementia, depression and suicide, amongst others in the general population. In sub-populations such as diabetes mellitus type 2, proliferative diabetic retinopathy is an independent predictor of ischemic stroke. According to various statistical sources, cryptogenic strokes account for 15 to 40% of the entire stroke incidence. The question to consider here is, whether a cryptogenic stroke is fully referable to unidentifiable aetiology or rather to underestimated risks. Considering the latter, translational research might be of great clinical utility to realise innovative predictive and preventive approaches, potentially benefiting high risk individuals and society at large. In this position paper, the consortium has combined multi-professional expertise to provide clear statements towards the paradigm change from reactive to predictive, preventive and personalised medicine in stroke management, the crucial elements of which are:Consolidation of multi-disciplinary expertise including family medicine, predictive and in-depth diagnostics followed by the targeted primary and secondary (e.g. treated cancer) prevention of silent brain infarctionApplication of the health risk assessment focused on sub-optimal health conditions to effectively prevent health-to-disease transitionApplication of AI in medicine, machine learning and treatment algorithms tailored to robust biomarker patternsApplication of innovative screening programmes which adequately consider the needs of young populations.

Clinic for Diagnostic and Interventional Radiology University Hospital Bonn Rheinische Friedrich Wilhelms Universität Bonn 53127 Bonn Germany

Department of Biology Faculty of Medicine in Plzen Charles University Prague Czech Republic

Department of Histology and Embryology and Biomedical Centre Faculty of Medicine in Plzen Charles University Prague Czech Republic

Department of Histology and Embryology Faculty of Medicine in Plzen Charles University Prague Czech Republic

Department of Neurology University Hospital Kralovske Vinohrady 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Neurology University Hospital Plzen and Faculty of Medicine in Plzen Charles University Prague Czech Republic

European Medical Association EMA Brussels Belgium

Experimental Ophthalmology University of Geneva 1205 Geneva Switzerland

Institute of Psychology Department of Clinical Psychology 2 University of Innsbruck Innsbruck Austria

Ophthalmology Department University Hospitals of Geneva 1205 Geneva Switzerland

Predictive Preventive and Personalised Medicine Department of Radiation Oncology University Hospital Bonn Rheinische Friedrich Wilhelms Universität Bonn 53127 Bonn Germany

Private Institute of Applied Ophthalmology Berlin Germany

Zobrazit více v PubMed

2021 Heart disease & stroke statistical update fact sheet global burden of disease [Internet]. American Heart Association; Available from: https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2021-Heart-and-Stroke-Stat-Update/2021_Stat_Update_factsheet_Global_Burden_of_Disease.pdf. Accessed 30 Aug 2022.

Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke Off J Int Stroke Soc. 2022;17:18–29. doi: 10.1177/17474930211065917. PubMed DOI

Learn about stroke [Internet]. World Stroke Organization; Available from: https://www.world-stroke.org/world-stroke-day-campaign/why-stroke-matters/learn-about-stroke. Accessed 30 Aug 2022.

Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis Basel Switz. 2003;16:280–285. doi: 10.1159/000071128. PubMed DOI

Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23. doi: 10.1186/s13167-016-0072-4. PubMed DOI PMC

Vermeer SE, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611–619. doi: 10.1016/S1474-4422(07)70170-9. PubMed DOI

Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28:1932–1939. doi: 10.1161/01.str.28.10.1932. PubMed DOI

Uehara T, Tabuchi M, Mori E. Risk factors for silent cerebral infarcts in subcortical white matter and basal ganglia. Stroke. 1999;30:378–382. doi: 10.1161/01.str.30.2.378. PubMed DOI

Lee SC, Park SJ, Ki HK, Gwon HC, Chung CS, Byun HS, et al. Prevalence and risk factors of silent cerebral infarction in apparently normal adults. Hypertens Dallas Tex. 1979;2000(36):73–77. doi: 10.1161/01.hyp.36.1.73-a. PubMed DOI

Matsui T, Arai H, Yuzuriha T, Yao H, Miura M, Hashimoto S, et al. Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke. 2001;32:1116–1119. doi: 10.1161/01.str.32.5.1116. PubMed DOI

Maeshima S, Moriwaki H, Ozaki F, Okita R, Yamaga H, Ueyoshi A. Silent cerebral infarction and cognitive function in middle-aged neurologically healthy subjects. Acta Neurol Scand. 2002;105:179–184. doi: 10.1034/j.1600-0404.2002.1o068.x. PubMed DOI

Waldstein SR, Siegel EL, Lefkowitz D, Maier KJ, Brown JRP, Obuchowski AM, et al. Stress-induced blood pressure reactivity and silent cerebrovascular disease. Stroke. 2004;35:1294–1298. doi: 10.1161/01.STR.0000127774.43890.5b. PubMed DOI

Kotani K, Osaki Y, Sakane N, Adachi S, Ishimaru Y. Risk factors for silent cerebral infarction in the elderly. Arch Med Res. 2004;35:522–524. doi: 10.1016/j.arcmed.2004.07.003. PubMed DOI

Kwon H-M, Kim BJ, Lee S-H, Choi SH, Oh B-H, Yoon B-W. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke. 2006;37:466–470. doi: 10.1161/01.STR.0000199081.17935.81. PubMed DOI

Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280–299. doi: 10.1161/01.str.32.1.280. PubMed DOI

Vogels EA, Lagro-Janssen AL, van Weel C. Sex differences in cardiovascular disease: are women with low socioeconomic status at high risk? Br J Gen Pract J R Coll Gen Pract. 1999;49:963–966. PubMed PMC

Herlitz J, Bång A, Karlson BW, Hartford M. Is there a gender difference in aetiology of chest pain and symptoms associated with acute myocardial infarction? Eur J Emerg Med Off J Eur Soc Emerg Med. 1999;6:311–315. doi: 10.1097/00063110-199912000-00007. PubMed DOI

Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke. 2000;31:1833–1837. doi: 10.1161/01.str.31.8.1833. PubMed DOI

Ramani S, Byrne-Logan S, Freund KM, Ash A, Yu W, Moskowitz MA. Gender differences in the treatment of cerebrovascular disease. J Am Geriatr Soc. 2000;48:741–745. doi: 10.1111/j.1532-5415.2000.tb04747.x. PubMed DOI

Golubnitschaja O. Changing long-held beliefs is never easy: a proposal for multi-modal approach in female healthcare – an integrative view. In the book: Healthcare overview - new perpectives (Ed: Vincenzo Costigliola V.), Book series “Advances in predictive, preventive and personalised medicine”, Springer Dordrecht Heidelberg New York London. V.1, 2012 ISBN 978–94–007–4602–2.

‘Silent strokes’ found accidentally need treatment, statement says [Internet]. American Heart Association; 2016. Available from: https://www.heart.org/en/news/2018/05/01/silent-strokes-found-accidentally-need-treatment-statement-says. Accessed 30 Aug 2022.

Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2003;34:392–396. doi: 10.1161/01.str.0000052631.98405.15. PubMed DOI

Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215–1222. doi: 10.1056/NEJMoa022066. PubMed DOI

Matsui T, Nemoto M, Maruyama M, Yuzuriha T, Yao H, Tanji H, et al. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer’s disease. Neurodegener Dis. 2005;2:299–304. doi: 10.1159/000092316. PubMed DOI

Neuropathology Group. Medical Research Council Cognitive Function and Aging Study Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) Lancet Lond Engl. 2001;357:169–75. doi: 10.1016/s0140-6736(00)03589-3. PubMed DOI

Jellinger KA, Mitter-Ferstl E. The impact of cerebrovascular lesions in Alzheimer disease–a comparative autopsy study. J Neurol. 2003;250:1050–1055. doi: 10.1007/s00415-003-0142-0. PubMed DOI

Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64:834–841. doi: 10.1212/01.WNL.0000152982.47274.9E. PubMed DOI

Makin SDJ, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry. 2013;84:893–900. doi: 10.1136/jnnp-2012-303645. PubMed DOI PMC

Bogousslavsky J, Regli F, Uske A. Thalamic infarcts: clinical syndromes, etiology, and prognosis. Neurology. 1988;38:837–848. doi: 10.1212/wnl.38.6.837. PubMed DOI

Tatemichi TK, Steinke W, Duncan C, Bello JA, Odel JG, Behrens MM, et al. Paramedian thalamopeduncular infarction: clinical syndromes and magnetic resonance imaging. Ann Neurol. 1992;32:162–171. doi: 10.1002/ana.410320207. PubMed DOI

Gold G, Kövari E, Herrmann FR, Canuto A, Hof PR, Michel J-P, et al. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke. 2005;36:1184–1188. doi: 10.1161/01.STR.0000166052.89772.b5. PubMed DOI

Fujikawa T, Yamawaki S, Touhouda Y. Silent cerebral infarctions in patients with late-onset mania. Stroke. 1995;26:946–949. doi: 10.1161/01.str.26.6.946. PubMed DOI

Yamashita H, Fujikawa T, Yanai I, Morinobu S, Yamawaki S. Cognitive dysfunction in recovered depressive patients with silent cerebral infarction. Neuropsychobiology. 2002;45:12–18. doi: 10.1159/000048667. PubMed DOI

Hamada T, Murata T, Omori M, Takahashi T, Kosaka H, Wada Y, et al. Abnormal nocturnal blood pressure fall in senile-onset depression with subcortical silent cerebral infarction. Neuropsychobiology. 2003;47:187–191. doi: 10.1159/000071213. PubMed DOI

Antelmi E, Fabbri M, Cretella L, Guarino M, Stracciari A. Late onset bipolar disorder due to a lacunar state. Behav Neurol. 2014;2014:780742. 10.1155/2014/780742. PubMed PMC

Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins J, et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke. 1997;28:1158–64. doi: 10.1161/01.str.28.6.1158. PubMed DOI

Kruit MC, van Buchem MA, Hofman PAM, Bakkers JTN, Terwindt GM, Ferrari MD, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291:427–434. doi: 10.1001/jama.291.4.427. PubMed DOI

Tietjen GE, Maly EF. Migraine and ischemic stroke in women A narrative review. Headache. 2020;60:843–863. doi: 10.1111/head.13796. PubMed DOI

Leung DYL, Tham CCY, Li FCH, Kwong YYY, Chi SCC, Lam DSC. Silent cerebral infarct and visual field progression in newly diagnosed normal-tension glaucoma: a cohort study. Ophthalmology. 2009;116:1250–1256. doi: 10.1016/j.ophtha.2009.02.003. PubMed DOI

Leung DYL, Tham CC. Normal-tension glaucoma: current concepts and approaches-a review. Clin Experiment Ophthalmol. 2022;50:247–259. doi: 10.1111/ceo.14043. PubMed DOI

Kubatka P, Mazurakova A, Koklesova L, Samec M, Sokol J, Samuel SM, et al. Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine. EPMA J. 2022;13:407–431. doi: 10.1007/s13167-022-00293-2. PubMed DOI PMC

Exploring the Link Between Stroke and Cancer [Internet]. Cure - oncology and cancer news for patients and caregivers; Available from: https://www.curetoday.com/view/exploring-the-link-between-stroke-and-cancer. Accessed 30 Aug 2022.

Aarnio K, Joensuu H, Haapaniemi E, Melkas S, Kaste M, Tatlisumak T, et al. Cancer in young adults with ischemic stroke. Stroke. 2015;46:1601–1606. doi: 10.1161/STROKEAHA.115.008694. PubMed DOI

Polivka J, Polivka J, Pesta M, Rohan V, Celedova L, Mahajani S, et al. Risks associated with the stroke predisposition at young age: facts and hypotheses in light of individualized predictive and preventive approach. EPMA J. 2019;10:81–99. doi: 10.1007/s13167-019-00162-5. PubMed DOI PMC

Golubnitschaja O, Flammer J. Individualised patient profile: clinical utility of Flammer syndrome phenotype and general lessons for predictive, preventive and personalised medicine. EPMA J. 2018;9:15–20. doi: 10.1007/s13167-018-0127-9. PubMed DOI PMC

Golubnitschaja O. (Ed.) Flammer syndrome – from phenotype to associated pathologies, prediction, prevention and personalisation V.11, 2019, ISBN 978–3–030–13549–2 ISBN 978–3–030–13550–8 (eBook), 10.1007/978-3-030-13550-8.

Evsevieva M, Sergeeva O, Mazurakova A, Koklesova L, Prokhorenko-Kolomoytseva I, Shchetinin E, et al. Pre-pregnancy check-up of maternal vascular status and associated phenotype is crucial for the health of mother and offspring. EPMA J. 2022;13:351–366. doi: 10.1007/s13167-022-00294-1. PubMed DOI PMC

Bubnov R, Polivka J, Zubor P, Konieczka K, Golubnitschaja O. “Pre-metastatic niches” in breast cancer: are they created by or prior to the tumour onset? “Flammer Syndrome” relevance to address the question. EPMA J. 2017;8:141–157. doi: 10.1007/s13167-017-0092-8. PubMed DOI PMC

Polivka J, Kralickova M, Polivka J, Kaiser C, Kuhn W, Golubnitschaja O. Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? EPMA J. 2017;8:119–127. doi: 10.1007/s13167-017-0087-5. PubMed DOI PMC

Deyell M, Garris CS, Laughney AM. Cancer metastasis as a non-healing wound. Br J Cancer. 2021;124:1491–1502. doi: 10.1038/s41416-021-01309-w. PubMed DOI PMC

Golubnitschaja O. Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification? EPMA J. 2017;8:17–22. doi: 10.1007/s13167-017-0086-6. PubMed DOI PMC

Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann Neurol. 2002;51:285–289. doi: 10.1002/ana.10111. PubMed DOI

Louka A-M, Sagris D, Ntaios G. Immunity, vascular aging and stroke. Curr Med Chem. 2022;29:5510–5521. doi: 10.2174/0929867329666220103101700. PubMed DOI

Kucera R, Pecen L, Topolcan O, Dahal AR, Costigliola V, Giordano FA, et al. Prostate cancer management: long-term beliefs, epidemic developments in the early twenty-first century and 3PM dimensional solutions. EPMA J. 2020;11:399–418. doi: 10.1007/s13167-020-00214-1. PubMed DOI PMC

Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5:11. doi: 10.1186/1878-5085-5-11. PubMed DOI PMC

Golubnitschaja O, Yeghiazaryan K, Abraham J-A, Schild HH, Costigliola V, Debald M, et al. Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes. Amino Acids. 2017;49:273–281. doi: 10.1007/s00726-016-2357-2. PubMed DOI

Fröhlich H, Patjoshi S, Yeghiazaryan K, Kehrer C, Kuhn W, Golubnitschaja O. Premenopausal breast cancer: potential clinical utility of a multi-omics based machine learning approach for patient stratification. EPMA J. 2018;9:175–186. doi: 10.1007/s13167-018-0131-0. PubMed DOI PMC

Golubnitschaja O, Filep N, Yeghiazaryan K, Blom HJ, Hofmann-Apitius M, Kuhn W. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine. Amino Acids. 2018;50:383–395. doi: 10.1007/s00726-017-2524-0. PubMed DOI

Zhong C, Yang J, Xu T, Xu T, Peng Y, Wang A, et al. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. Neurology. 2017;89:805–812. doi: 10.1212/WNL.0000000000004257. PubMed DOI PMC

Jia Y, Guo D, Zhang K, Yang P, Zang Y, Sun L, et al. Causal associations of serum matrix metalloproteinase-8 level with ischaemic stroke and ischaemic stroke subtypes: a Mendelian randomization study. Eur J Neurol. 2021;28:2543–2551. doi: 10.1111/ene.14878. PubMed DOI

Hill MD. Stroke and diabetes mellitus. Handb Clin Neurol. 2014;126:167–174. doi: 10.1016/B978-0-444-53480-4.00012-6. PubMed DOI

van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. 2020;8:325–336. doi: 10.1016/S2213-8587(19)30405-X. PubMed DOI PMC

Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet Lond Engl. 2010;376:124–136. doi: 10.1016/S0140-6736(09)62124-3. PubMed DOI

Hu K, Jiang M, Zhou Q, Zeng W, Lan X, Gao Q, et al. Association of diabetic retinopathy with stroke: a systematic review and meta-analysis. Front Neurol. 2021;12:626996. doi: 10.3389/fneur.2021.626996. PubMed DOI PMC

Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: a systematic review and meta-analysis. JAMA Ophthalmol. 2017;135:586–593. doi: 10.1001/jamaophthalmol.2017.0988. PubMed DOI PMC

Modjtahedi BS, Wu J, Luong TQ, Gandhi NK, Fong DS, Chen W. Severity of diabetic retinopathy and the risk of future cerebrovascular disease, cardiovascular disease, and all-cause mortality. Ophthalmology. 2021;128:1169–1179. doi: 10.1016/j.ophtha.2020.12.019. PubMed DOI

Evaluation of Cryptogenic Stroke [Internet]. American College of Cardiology; Available from: https://www.acc.org/latest-in-cardiology/articles/2019/10/10/23/20/evaluation-of-cryptogenic-stroke. Accessed 30 Aug 2022.

Torres Crigna A, Link B, Samec M, Giordano FA, Kubatka P, Golubnitschaja O. Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine. EPMA J. 2021;12(3):1–41. doi: 10.1007/s13167-021-00248-z. PubMed DOI PMC

Koklesova L, Samec M, Liskova A, Zhai K, Büsselberg D, Giordano FA, Kubatka P, Golunitschaja O. Mitochondrial impairments in aetiopathology of multifactorial diseases: common origin but individual outcomes in context of 3P medicine. EPMA J. 2021;12(1):27–40. doi: 10.1007/s13167-021-00237-2. PubMed DOI PMC

Koklesova L, Mazurakova A, Samec M, Kudela E, Biringer K, Kubatka P, Golubnitschaja O. Mitochondrial health quality control: measurements and interpretation in the framework of predictive, preventive, and personalized medicine. EPMA J. 2022 doi: 10.1007/s13167-022-00281-6. PubMed DOI PMC

Golubnitschaja O, Liskova A, Koklesova L, Samec M, Biringer K, Büsselberg D, Podbielska H, Kunin AA, Evsevyeva ME, Shapira N, Paul F, Erb C, Dietrich DE, Felbel D, Karabatsiakis A, Bubnov R, Polivka J, Polivka J, Jr, Birkenbihl C, Fröhlich H, Hofmann-Apitius M, Kubatka P. Caution, “normal” BMI: health risks associated with potentially masked individual underweight EPMA Position Paper 2021. EPMA J. 2021;12(3):1–22. doi: 10.1007/s13167-021-00251-4. PubMed DOI PMC

Wang W, Yan Y, Guo Z, Hou H, Garcia M, Tan X, Anto EO, Mahara G, Zheng Y, Li B, Wang Y, Guo X, Golubnitschaja O, ALL AROUND SUBOPTIMAL HEALTH A joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive Preventive and Personalised Medicine. EPMA J. 2021;12(4):1–31. doi: 10.1007/s13167-021-00253-2. PubMed DOI PMC

The paradigm change from reactive medical services to 3PM in ischemic stroke: a holistic approach utilising tear fluid multi-omics, mitochondria as a vital biosensor and AI-based multi-professional data interpretation

Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells - A potential contribution to the predictive, preventive, and personalized medicine

Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation